reviewTop 1% cited
High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993
Journal of Clinical Oncology · 1999 · Vol. 17(7) · pp. 2105–2105
Michael B. Atkins✉Michael T. Lotze(Novartis (Switzerland))Janice P. Dutcher(Novartis (Switzerland))Richard I. Fisher(Novartis (Switzerland))Geoffrey R. Weiss(Novartis (Switzerland))Kim Margolin(Novartis (Switzerland))Jeff Abrams(Novartis (Switzerland))Mario Sznol(Novartis (Switzerland))David Parkinson(Novartis (Switzerland))Michael Hawkins(Novartis (Switzerland))Carolyn Paradise(Novartis (Switzerland))Lori Kunkel(Novartis (Switzerland))Steven A. Rosenberg
Abstract
High-dose IL-2 treatment seems to benefit some patients with metastatic melanoma by producing durable CRs or PRs and should be considered for appropriately selected melanoma patients.
CAR-T cell therapy researchImmunotherapy and Immune ResponsesCancer Immunotherapy and BiomarkersMedicineRegimenToxicitySurgeryBolus (digestion)Clinical trialInternal medicineMetastatic melanomaConfidence intervalChemotherapy
MeSH terms
AdultAgedAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansInterleukin-2MaleMelanomaMiddle AgedRecombinant ProteinsRisk FactorsUnited StatesSurvival RateSalvage TherapyTreatment Outcome
Funding
- National Cancer Institute
Citations
2,025
FWCI
11.62
field-weighted impact
References
38
Percentile
99%
vs. same field & year
Citations per year
Cited by
Cytokines in Cancer Immunotherapy
Cancers · 2011 · 677 citations
IL-2: The First Effective Immunotherapy for Human Cancer
The Journal of Immunology · 2014 · 1,253 citations
Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
Clinical Cancer Research · 2011 · 2,095 citations
High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal
Nature reviews. Immunology · 2005 · 2,484 citations
Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study
Annals of Surgical Oncology · 2005 · 489 citations
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
The Lancet Oncology · 2016 · 1,657 citations
Cytokines in clinical cancer immunotherapy
British Journal of Cancer · 2018 · 1,189 citations
Protein therapeutics: a summary and pharmacological classification
Nature Reviews Drug Discovery · 2007 · 2,066 citations
References
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
Journal of Clinical Oncology · 1996 · 2,101 citations
Nonparametric Estimation from Incomplete Observations
Journal of the American Statistical Association · 1958 · 38,793 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.